DelNS1 SARS CoV2 RBD LAIV - Univeristy of Hong kong
Alternative Names: DelNS1-nCoV-RBD LAIVLatest Information Update: 28 Apr 2025
At a glance
- Originator University of Hong Kong
- Class Attenuated vaccines; COVID-19 vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Hong Kong (Intranasal, Spray)
- 22 Mar 2021 University of Hong Kong plans a phase I trial for COVID-2019 infections (Prevention) in March 2021 (Intranasal) (NCT04809389)
- 18 Mar 2021 Preclinical trials in COVID-2019 infections (Prevention) in Hong Kong (Intranasal) before March 2021